Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

NHS Framework for the North of England, Branded Medicine

The NHS Commissioning Board (operating under the name of NHS England)

This public procurement record has 2 releases in its history.

Award

01 Mar 2022 at 12:15

Award Notice
Tender

15 Sep 2021 at 13:10

Tender Notice
Summary of the contracting process

The NHS Commissioning Board, operating under the name of NHS England, has initiated a tender titled "NHS Framework for the North of England, Branded Medicines," specified under the CPV classification for Pharmaceutical products. This procurement process is currently at the Tender stage, with lots including Tranche B and various other related products. The contract period spans from 1 March 2022 to 29 February 2024, with potential extensions of up to 24 months at the authority's discretion. Important dates include the tender end date of 20 October 2021, which marks the deadline for expressions of interest and bid submissions through the specified eTendering portal.

This tender presents significant opportunities for pharmaceutical businesses, particularly those focused on branded medicines and biosimilars. Suppliers capable of delivering pharmaceutical products efficiently and complying with NHS regulations will find this procurement especially advantageous. Both large enterprises and small to medium-sized enterprises (SMEs) can compete for contracts listed under this framework, allowing for collaboration and participation in a diversified marketplace that is critical for growth in the healthcare sector.

How relevant is this notice?

Notice Information

Notice Title

NHS Framework for the North of England, Branded Medicine

Notice Description

HS Framework for the North of England, Branded Medicines - Tranche B, Annual Tranche and Insulin Aspart Biosimilar (Trurapi(r))

Lot Information

CM/PHR/20/5600/01 - NHS Framework for the NOFE, Branded Medicines - Tranche B

CM/PHR/20/5600/01 - NHS Framework for the North of England, Branded Medicines -Tranche B - 1 March 2022 to 29 February 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/20/5600/02 - NHS Framework for the NOFE, Branded Medicines-Annual Tranche

CM/PHR/20/5600/02 - NHS Framework for the North of England, Branded Medicines - Annual Tranche Products. Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

CM/PHR/20/5600/03- NHS Framework for Insulin Aspart Biosimilar (Trurapi(r))-SofE

CM/PHR/20/5600/03- NHS Framework for Insulin Aspart Biosimilar (Trurapi(r)), South of England - Period of framework: 1 March 2022 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 6 months.

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 6 months.

CM/PHR/20/5600/04-NHS Framework for Insulin Aspart Biosimilar (Trurapi(r)), London

CM/PHR/20/5600/04 - NHS Framework for Insulin Aspart Biosimilar (Trurapi(r)), London - Period of framework: 1 March 2022 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 18 months.

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 18 months.

CM/PHR/20/5600/05 - NHS Framework for Insulin Aspart Biosimilar (Trurapi(r)), MaE

CM/PHR/20/5600/05 - NHS Framework for Insulin Aspart Biosimilar (Trurapi(r)), Midlands and East - Period of framework: 1 March 2022 to 28 February 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-02e103
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/005550-2022
Current Stage
Award
All Stages
Tender, Award

Procurement Classification

Notice Type
Tender Notice
Procurement Type
Framework
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Large, SME

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
£863,999,552 £100M-£1B
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
£1

Notice Dates

Publication Date
1 Mar 20224 years ago
Submission Deadline
20 Oct 2021Expired
Future Notice Date
Not specified
Award Date
7 Feb 20224 years ago
Contract Period
1 Mar 2022 - 28 Feb 2023 6-12 months
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Cancelled
Awards Status
Active
Contracts Status
Active

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
The NHS Commissioning Board (operating under the name of NHS England)
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
RUNCORN
Postcode
WA7 2ES
Postcode Area
Warrington
Country
England
Major Region (ITL 1)
TLD North West (England)
Basic Region (ITL 2)
TLD7 Merseyside
Small Region (ITL 3)
TLD71 East Merseyside
Delivery Location
Not specified
Local Authority
Halton
Electoral Ward
Halton Lea
Westminster Constituency
Runcorn and Helsby

Supplier Information

Number of Suppliers
27
Supplier Names

Accord-UK Ltd

Amgen Ltd

Aventis Pharma ltd t/a Sanofi

Bayer Ltd

Biogen

Bristol Myers Squibb

CST Pharma Limited

Celltrion Healthcare United Kingdom Limited

Eli Lilly and Company Ltd

Gedeon Richter UK Ltd

Gilead Sciences Limited

GlaxoSmithKline UK Limited

Ipsen

Janssen-Cilag Ltd

Merck Serono Limited

Merck Sharpe and Dohme (UK) Limited

Napp Pharmaceuticals Ltd

Novo Nordisk

Pfizer Ltd

Roche Products Ltd

Sobi (Swedish Orphan Biovitrum Ltd)

Takeda UK Ltd

Teva UK Limited

Thornton and Ross Ltd

UCB Pharma Ltd

UL Global Pharma

Zentiva Pharma UK Ltd

Further Information

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...